Corporate Profile

Sol-Gel was successful in developing pioneer topical drugs, Twyneo® and Epsolay®, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022. We are developing topical patidegib that is expected to be approved for the treatment of Gorlin syndrome and topical erlotinib for the treatment of pachyonychia congenita and other rare skin indications.

Show all

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation

Subscribe to our email alerts

Get new updates directly to your inbox

Scroll to Top